CD274 and neoplasm: The sensitivity to anti-PD-L1 therapy can also be evaluated by tumor microenvironment immune types (TMIT), which is a tumor classification method based on the PD-L1 status and the presence or absence of tumor-infiltrating lymphocytes (TILs) (16).